Connection | Profiles RNS

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

Cobleigh, Melody

One or more keywords matched the following items that are connected to Cobleigh, Melody

Item Type	Name
Academic Article	Is trastuzumab every three weeks ready for prime time?
Academic Article	A case of herceptin cardiotoxicity.
Academic Article	Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.
Academic Article	Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.
Academic Article	Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.
Academic Article	Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43.
Academic Article	Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.
Academic Article	Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
Academic Article	Cardiovascular Monitoring With Trastuzumab Therapy: How Frequent Is Too Frequent?
Academic Article	First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report.
Academic Article	First-line Herceptin monotherapy in metastatic breast cancer.
Academic Article	Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
Academic Article	First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report.
Academic Article	Trastuzumab-induced cardiac toxicity: Is serial assessment of left ventricular ejection fraction during treatment necessary?
Academic Article	De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
Academic Article	Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells.
Academic Article	Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry.
Academic Article	Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial.
Academic Article	Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer.
Concept	Trastuzumab

Search Criteria

Trastuzumab